NYX-PCSK9i + Lipitor = No effect on liver enzymes… that in itself is amazing. Throw in the inhibition of atherosclerotic plaque formation and you’ve got an incredibly compelling compound.
Shareholders understandably upset and disgruntled by the delays, but clearly they’ve been busy behind the scenes shown by optimizing an analog of NYX-PCSK9i. Never assume a lack of news equates to a lack of work, quite often it's the opposite.
Likewise the improved Phase I/IIa Study permutation shows a keenness for lost time from management and the board.
@reon1 - I take this evolution to a Ph2 study as creating significant value driving any future licensing deal. Personally, I’m happy with this and would rather see them progress, what is turning out to be an incredibly remarkable small molecule compound, then sell early.
As for their NYR-BI02 TRPC 3/6/7 blocker; while interesting to me, it isn’t the main game imho, and just more cream on top. Plus it’s a wonderful space to be playing in especially with Walter Reed.
I'm in the cue for more, but whether or not I get filled by these shortsighted sellers is another thing.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)